Novo Nordisk obesity drug linked to rare cause of sight loss

The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.

ACC25: Ozempic shows its value in PAD

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

FDA approves MACE label claim for Lilly’s Trulicity

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly